about
Clinical applications of PD-L1 bioassays for cancer immunotherapy.Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China.Antitumor Effects of Laminaria Extract Fucoxanthin on Lung Cancer.Role of Autophagy and Apoptosis in Non-Small-Cell Lung Cancer.Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapyThe next generation of immunotherapy: keeping lung cancer in check.Treating EGFR mutation resistance in non-small cell lung cancer - role of osimertinib.New prognostic biomarkers and therapeutic effect of bevacizumab for patients with non-small-cell lung cancer.Clinical trials of tyrosine kinase inhibitors for lung cancer in China: a reviewIdentification of pyrrolopyrimidine derivative PP-13 as a novel microtubule-destabilizing agent with promising anticancer propertiesSevere nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report.IL-33 blockade suppresses tumor growth of human lung cancer through direct and indirect pathways in a preclinical model.Clinical trials of CAR-T cells in ChinaExtraordinary clinical benefit to sequential treatment with targeted therapy and immunotherapy of a BRAF V600E and PD-L1 positive metastatic lung adenocarcinoma.The clinical significance of CXCL5 in non-small cell lung cancer.Preventive effect of kampo medicine (hangeshashin-to, TJ-14) plus minocycline against afatinib-induced diarrhea and skin rash in patients with non-small cell lung cancer.Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy.SEOM-SERAM-SEMNIM guidelines on the use of functional and molecular imaging techniques in advanced non-small-cell lung cancer.Cancer immunotherapy beyond immune checkpoint inhibitors.Current Development Status of MEK Inhibitors.Inhibition of protein kinase CK2 sensitizes non-small cell lung cancer cells to cisplatin via upregulation of PML.Real-world usage and clinical outcomes of alectinib among post-crizotinib progression anaplastic lymphoma kinase positive non-small-cell lung cancer patients in the USA.Next generation of immune checkpoint therapy in cancer: new developments and challenges.Dichloroacetate enhances the antitumor efficacy of chemotherapeutic agents via inhibiting autophagy in non-small-cell lung cancer.Aptamers: novelty tools for cancer biology.Overexpression of CLC-3 is regulated by XRCC5 and is a poor prognostic biomarker for gastric cancer
P2860
Q33702815-2B800256-55CE-499E-A426-71C1AE75A580Q33876861-A0E4A41E-2334-4E2A-9DF6-727250239354Q37678305-809E3769-27F6-4FAB-82F5-A6F367329AC4Q37690890-E6D58DB4-3D13-4173-B850-BB5CDD186274Q38598893-6E9BE8AC-8CA0-4799-98E3-03FDEA852E5EQ38824489-7DE90D4F-2C2A-48A7-A873-56E15B8737F8Q41189462-0D9C8B2B-A491-4CC8-BDA2-3A0D57A765EEQ41283854-DB58EA38-B1D1-42C9-B99D-F9805442D4A6Q41292062-AAA66BA2-6B8A-4B77-98DD-AE239A971A02Q41580211-5DC8610A-E6D0-4969-BEAF-00CE65174593Q41896400-B4EE56CD-91B0-4A94-9B88-86FE40B7738DQ41972983-92884BEB-3529-410E-940A-6A9FA90E9B3AQ42654456-3FC3AFD3-BE1E-45CF-AC0B-6844576F23B5Q46299389-8BEE53CA-92CF-4D7D-9B35-3BBA468E107FQ47101861-C69B777F-5F76-4111-84FE-00D02D0CEEA4Q47102325-8C9CC383-D055-4B41-B16D-8A437B675308Q47157402-41A29010-4C50-4EED-96B7-1FB2E2F30054Q47284858-38B7CF4D-6857-4D92-8B20-51F40FCD1E07Q47554248-E41ACEEE-862E-45A2-9639-C5A8D10BE057Q47735535-8D70B376-E219-4A68-A974-76672A02C2CAQ48026912-C1EF8280-B160-42ED-B268-C7E7F7209002Q49307383-FA40ED67-E3D1-4379-9EA0-4FCAF9099A5FQ52653710-590828BE-9D5A-4B6C-B581-1248A5002500Q55098336-A5F9BF77-42B2-4809-BAF1-64E714A69DBFQ55285633-52602833-FFE1-420A-9EB7-5426FF68AC97Q58741539-32F932AE-2FF1-4EE2-83B9-BF0C1C8D78D0
P2860
description
2016 nî lūn-bûn
@nan
2016 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Emerging therapeutic agents for lung cancer
@ast
Emerging therapeutic agents for lung cancer
@en
Emerging therapeutic agents for lung cancer
@nl
type
label
Emerging therapeutic agents for lung cancer
@ast
Emerging therapeutic agents for lung cancer
@en
Emerging therapeutic agents for lung cancer
@nl
prefLabel
Emerging therapeutic agents for lung cancer
@ast
Emerging therapeutic agents for lung cancer
@en
Emerging therapeutic agents for lung cancer
@nl
P2093
P2860
P1476
Emerging therapeutic agents for lung cancer
@en
P2093
Amanda Shreders
Bhagirathbhai Dholaria
Yanyan Lou
P2860
P2888
P356
10.1186/S13045-016-0365-Z
P407
P5008
P577
2016-12-09T00:00:00Z
P6179
1013590265